Merck at ASCO: Expanding Beyond Keytruda

Merck & Co. (MRK) presented its strategic vision at the American Society of Clinical Oncology Annual Meeting 2025, emphasizing portfolio diversification beyond Keytruda into areas like HIV, vaccines, and cardiovascular treatments, while also expanding its oncology pipeline. Keytruda remains a significant revenue driver with 56 FDA-approved indications and promising subcutaneous formulation uptake, and Merck anticipates launching 20 new growth drivers, 13 in oncology, with a late-stage pipeline representing a commercial opportunity exceeding $25 billion. Despite these advancements, challenges persist in sustaining oncology leadership amid Keytruda's loss of exclusivity in the late 2020s.

Analysis

Merck & Co. outlined a strategic vision at ASCO 2025 centered on diversifying its oncology portfolio beyond the flagship Keytruda and expanding into new therapeutic areas, while simultaneously deepening its oncology pipeline. Keytruda remains a cornerstone, with 41 of Merck's 56 U.S. approved indications and 35 positive Phase III trials; the company anticipates a 30-40% U.S. uptake for its subcutaneous (subQ) formulation within 18-24 months post-launch, currently under FDA/EMA review. This subQ formulation, offering a rapid injection time of approximately two minutes, is positioned as a significant patient and healthcare system benefit, particularly in earlier disease stages and oral combination settings, despite potential initial reimbursement delays pending permanent J-code assignment. The company is advancing a robust late-stage pipeline with a non-risk adjusted commercial opportunity exceeding $25 billion, notably excluding contributions from subQ pembrolizumab or earlier-stage assets like the PD-1 VEGF bispecific MK-2010. This pipeline, featuring 20 planned new growth drivers (13 in oncology), is critical for navigating Keytruda's loss of exclusivity anticipated in 2028-2032, with antibody-drug conjugates (ADCs) driving over half of this projected opportunity. Key assets highlighted include Sac TMT (Trop-2 ADC), with nine potential first-in-class indications and strong data in EGFR-mutated NSCLC and TNBC; MK-1084 (KRAS G12C inhibitor), showing a 77% overall response rate with pembrolizumab in PD-L1 positive NSCLC; and MK-2140 for diffuse large B-cell lymphoma. Merck acknowledges the evolving market, including competition for PD-1/VEGF bispecifics (where MK-2010 is advancing, initially in China) and TROP-2 ADCs, emphasizing differentiation through its development strategy and combination potential. The company's extensive late-stage program, with over 60 registrational trials, supported by a strong commercial engine, underpins its confidence in executing this strategic pivot and translating its broad pipeline into sustained growth while navigating policy considerations.

Key Decisions for Investors

• Investors should closely monitor the clinical trial readouts and regulatory progress of Merck's late-stage oncology pipeline, particularly for key ADCs like Sac TMT and the KRAS inhibitor MK-1084, as these are critical to achieving the projected >$25 billion commercial opportunity and mitigating Keytruda patent expiries.
• The adoption trajectory of subcutaneous Keytruda, especially post-permanent J-code assignment, and Merck's ability to differentiate its TROP-2 ADC and PD-1/VEGF bispecific in competitive markets will be key indicators of near-to-medium term commercial success and should be tracked.
• Assess Merck's progress in diversifying into non-oncology therapeutic areas such as HIV, vaccines, and cardiovascular, alongside strategic business development, as these represent long-term growth vectors beyond the current oncology-focused pipeline.
• Evaluate Merck's execution on its multifaceted development strategy, including biomarker-defined populations and novel combinations, and its navigation of policy changes (e.g., MFN, IRA implications) as crucial factors for realizing its ambitious growth targets.